00068-7/asset/096c9be0-b6df-496c-ad71-95f35e424b2e/main.assets/gr2_lrg.jpg)
semaglutide and cirrhosis 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Semaglutide for Fatty Liver Disease:
Description
Many patients report that alcohol tolerance drops on semaglutide, meaning smaller amounts cause disproportionate effects
The abdomen is the easiest site to learn on
The weight loss trajectory of this medication suggests that moderate sleep apnea may resolve entirely for many users, while severe cases may see substantial enough improvement to reduce CPAP pressure requirements or allow alternative, less cumbersome therapies
Particularly, the safety profiles of GLP-1RA drugs that are still under development require further investigation with larger samples
